Lincoln Pharmaceuticals Limited (LINCOLN.NS)
INR 552.6
(3.05%)
INR 552.6
(3.05%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -127.63 Million INR | -317.83% |
| 2022 | -30.54 Million INR | 37.53% |
| 2021 | -48.9 Million INR | 55.21% |
| 2020 | -109.18 Million INR | -138.79% |
| 2019 | 281.51 Million INR | -0.0% |
| 2018 | 281.51 Million INR | -48.55% |
| 2017 | 547.18 Million INR | 4.92% |
| 2016 | 521.52 Million INR | -18.1% |
| 2015 | 636.79 Million INR | -1.49% |
| 2014 | 646.44 Million INR | 12.92% |
| 2013 | 572.48 Million INR | 0.34% |
| 2012 | 570.52 Million INR | 20.05% |
| 2011 | 475.25 Million INR | 54.23% |
| 2010 | 308.14 Million INR | 89.12% |
| 2009 | 162.93 Million INR | 48.38% |
| 2008 | 109.8 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | 100.0% |
| 2023 Q3 | 1.7 Billion INR | 1293.45% |
| 2023 Q1 | 1.25 Billion INR | 4213.06% |
| 2023 FY | -127.63 Million INR | -317.83% |
| 2023 Q4 | -127.63 Million INR | -107.47% |
| 2023 Q2 | -143.09 Million INR | -111.39% |
| 2022 Q4 | -30.54 Million INR | -102.49% |
| 2022 FY | -30.54 Million INR | 37.53% |
| 2022 Q2 | 83.03 Million INR | -92.82% |
| 2022 Q3 | 1.22 Billion INR | 1374.76% |
| 2022 Q1 | 1.15 Billion INR | 2463.93% |
| 2021 Q4 | -48.9 Million INR | -104.36% |
| 2021 Q1 | 945.05 Million INR | 965.54% |
| 2021 FY | -48.9 Million INR | 55.21% |
| 2021 Q2 | -64.65 Million INR | -106.84% |
| 2021 Q3 | 1.12 Billion INR | 1833.06% |
| 2020 FY | -109.18 Million INR | -138.79% |
| 2020 Q3 | 1.05 Billion INR | 939.25% |
| 2020 Q4 | -109.18 Million INR | -110.34% |
| 2020 Q1 | 487.97 Million INR | 73.34% |
| 2020 Q2 | -125.85 Million INR | -125.79% |
| 2019 Q3 | 605.35 Million INR | 515.65% |
| 2019 Q1 | 267.34 Million INR | -5.04% |
| 2019 Q2 | 98.32 Million INR | -63.22% |
| 2019 Q4 | 281.51 Million INR | -53.5% |
| 2019 FY | 281.51 Million INR | -0.0% |
| 2018 Q3 | 239.23 Million INR | -28.78% |
| 2018 Q2 | 335.89 Million INR | 31.32% |
| 2018 Q1 | 255.77 Million INR | -53.26% |
| 2018 FY | 281.51 Million INR | -48.55% |
| 2018 Q4 | 281.51 Million INR | 17.68% |
| 2017 FY | 547.18 Million INR | 4.92% |
| 2017 Q3 | 200.98 Million INR | -51.58% |
| 2017 Q1 | 217.79 Million INR | -58.24% |
| 2017 Q4 | 547.18 Million INR | 172.25% |
| 2017 Q2 | 415.12 Million INR | 90.6% |
| 2016 Q3 | 121.8 Million INR | -75.39% |
| 2016 FY | 521.52 Million INR | -18.1% |
| 2016 Q4 | 521.52 Million INR | 328.18% |
| 2016 Q2 | 494.95 Million INR | 293.81% |
| 2016 Q1 | 125.68 Million INR | -80.26% |
| 2015 FY | 636.79 Million INR | -1.49% |
| 2015 Q3 | 5.35 Million INR | -99.15% |
| 2015 Q2 | 632.81 Million INR | 449.82% |
| 2015 Q4 | 636.79 Million INR | 11793.9% |
| 2015 Q1 | 115.09 Million INR | -82.2% |
| 2014 Q1 | 49.89 Million INR | -91.29% |
| 2014 Q4 | 646.44 Million INR | 1072.0% |
| 2014 Q3 | 55.15 Million INR | -93.72% |
| 2014 FY | 646.44 Million INR | 12.92% |
| 2014 Q2 | 878.66 Million INR | 1661.2% |
| 2013 FY | 572.48 Million INR | 0.34% |
| 2013 Q3 | 96.22 Million INR | -86.82% |
| 2013 Q4 | 572.48 Million INR | 494.92% |
| 2013 Q1 | 96.61 Million INR | -83.07% |
| 2013 Q2 | 730.18 Million INR | 655.76% |
| 2012 Q4 | 570.52 Million INR | 392.4% |
| 2012 Q2 | -115.86 Million INR | 0.0% |
| 2012 Q3 | 115.86 Million INR | 200.0% |
| 2012 FY | 570.52 Million INR | 20.05% |
| 2011 Q4 | 475.25 Million INR | 0.0% |
| 2011 FY | 475.25 Million INR | 54.23% |
| 2010 FY | 308.14 Million INR | 89.12% |
| 2009 FY | 162.93 Million INR | 48.38% |
| 2008 FY | 109.8 Million INR | 0.0% |
| 2008 Q4 | 109.8 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 103.302% |
| Hester Biosciences Limited | 2.29 Billion INR | 105.572% |
| Aarti Drugs Limited | 5.54 Billion INR | 102.3% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 104.887% |
| Albert David Limited | -278.36 Million INR | 54.148% |
| Alembic Limited | 66.9 Million INR | 290.789% |
| Alkem Laboratories Limited | -1.6 Billion INR | 92.069% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | 155.511% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 103.869% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -591.955% |
| Brooks Laboratories Limited | 49.48 Million INR | 357.933% |
| Eris Lifesciences Limited | 13.8 Billion INR | 100.924% |
| FDC Limited | -57.75 Million INR | -121.011% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 95.51% |
| Gufic Biosciences Limited | 3.19 Billion INR | 103.996% |
| Hikal Limited | 7.96 Billion INR | 101.602% |
| Ind-Swift Limited | 9.5 Billion INR | 101.342% |
| Innova Captab Limited | 2.33 Billion INR | 105.469% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 88.41% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 90.817% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 100.471% |
| Lupin Limited | 19.38 Billion INR | 100.658% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 113.08% |
| Medico Remedies Limited | 78.67 Million INR | 262.23% |
| Morepen Laboratories Limited | -231.17 Million INR | 44.787% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 102.073% |
| Orchid Pharma Limited | -1.31 Billion INR | 90.285% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 94.564% |
| RPG Life Sciences Limited | -364.7 Million INR | 65.002% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 206.33% |
| Sigachi Industries Limited | 859.94 Million INR | 114.843% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 101.272% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 188.041% |
| Themis Medicare Limited | 764.96 Million INR | 116.686% |
| Unichem Laboratories Limited | 931.91 Million INR | 113.696% |
| Vaishali Pharma Limited | 119.13 Million INR | 207.137% |
| Wanbury Limited | 1.1 Billion INR | 111.542% |
| Windlas Biotech Limited | -273.04 Million INR | 53.253% |
| ZIM Laboratories Limited | 983.6 Million INR | 112.977% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 96.927% |
| Ipca Laboratories Limited | 11.41 Billion INR | 101.118% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 99.824% |
| Venus Remedies Limited | -267.7 Million INR | 52.321% |
| Sakar Healthcare Limited | 790.93 Million INR | 116.138% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 103.456% |
| Divi's Laboratories Limited | -39.77 Billion INR | 99.679% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 97.454% |
| Mankind Pharma Limited | -1.74 Billion INR | 92.7% |
| Sequent Scientific Limited | 4.17 Billion INR | 103.055% |
| Laurus Labs Limited | 24.35 Billion INR | 100.524% |
| Neuland Laboratories Limited | -214.05 Million INR | 40.372% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 104.524% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 97.021% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 103.263% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 48.697% |
| Wockhardt Limited | 18.27 Billion INR | 100.699% |
| Bal Pharma Limited | 1.26 Billion INR | 110.101% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 100.988% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 88.975% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | 65.178% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 97.683% |
| Shilpa Medicare Limited | 9.06 Billion INR | 101.407% |
| Valiant Laboratories Limited | 649.9 Million INR | 119.64% |
| Ajanta Pharma Limited | -954.9 Million INR | 86.633% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | 142.892% |
| Granules India Limited | 9.28 Billion INR | 101.374% |
| Medicamen Biotech Limited | 160.31 Million INR | 179.617% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 376.207% |
| Piramal Enterprises Limited | 491.39 Billion INR | 100.026% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 100.401% |
| NATCO Pharma Limited | -5.81 Billion INR | 97.806% |
| Suven Life Sciences Limited | -1.63 Billion INR | 92.182% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 106.603% |
| Strides Pharma Science Limited | 23.25 Billion INR | 100.549% |
| Indoco Remedies Limited | 6.47 Billion INR | 101.971% |
| Alpa Laboratories Limited | 35.36 Million INR | 460.937% |
| Lasa Supergenerics Limited | 205.79 Million INR | 162.021% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 86.447% |